EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access

Mizoribine or Cyclophosphamide for Lupus Nephritis

Zheyi Dong, Ping Luo, Shiren Sun, Zhaohui Ni, Yani He, Xiangyang Huang, Zhangsuo Liu, Zhenbiao Wu, Xinzhou Zhang, Yunhua Liao, Jianhong Zhao, Hongli Lin und 25 weitere

JAMA Network Open · 2025

DOI: 10.1001/jamanetworkopen.2025.0648 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, 2025. Verfasst von Zheyi Dong und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People's Liberation Army, State K…. Hauptthemen laut MEDLINE: Cyclophosphamide, Lupus Nephritis, Ribonucleosides, Immunosuppressive Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Lupus nephritis is typically treated with intravenous cyclophosphamide, which is associated with serious adverse effects. Oral mizoribine may be an alternative for induction therapy of lupus nephritis. However, large-scale, long-term, randomized clinical studies of mizoribine are lacking.

Objective

To assess the efficacy and safety of oral mizoribine vs intravenous cyclophosphamide as induction therapy for Chinese patients with lupus nephritis. Design, Setting, and Participants This prospective, multicenter, parallel-group, open-label, phase 3 randomized clinical trial recruited patients with class III, III+V, IV, IV+V, or V lupus nephritis aged 18 to 70 years from 40 centers in China. Inclusion criteria included 24-hour urinary protein level of 1.0 g or higher and systemic lupus erythematosus disease activity index of 8 or higher. The first patient was enrolled on November 29, 2014, and the study finished March 14, 2019. The follow-up period was 52 weeks. Data were analyzed from September 4, 2019, to January 21, 2020.

Interventions

Oral mizoribine (50 mg, 3 times a day) or cyclophosphamide (6 intravenous doses at 0.5-1.0 g/m 2 body surface area, with a maximum dose of 1.0 g/d) for 52 weeks plus oral glucocorticoid. Main Outcomes and Measures Total remission rate (complete remission rate plus partial remission rate) after 52 weeks (prespecified).

Results

A total of 250 patients were randomized, and 243 patients (mean [SD] age, 34.6 [10.7] years, 213 women [87.7%]) were treated (123 patients [50.6%] in the mizoribine group and 120 patients [49.4%] in the cyclophosphamide group). The total remission rate at 52 weeks was 66.1% (76 of 115 patients) in the mizoribine group and 76.8% (86 of 112 patients) in the cyclophosphamide group, and the relative risk ratio (mizoribine vs cyclophosphamide) was 0.861 (95% CI, 0.729-1.016). The lower limit of this 2-sided 95% CI was greater than the noninferiority margin of 0.726, indicating that mizoribine was noninferior to cyclophosphamide. Changes in other immune parameters and kidney function were generally similar between the groups. The incidence of any treatment-related treatment-emergent adverse events was 80.5% (99 of 123 patients) in the mizoribine group and 78.7% (96 of 122 patients) in the cyclophosphamide group, and the most frequent adverse event in both groups was upper respiratory tract infection (41 patients [33.3%] and 37 patients [30.3%], respectively). Conclusions and Relevance This randomized clinical trial shows that compared with intravenous cyclophosphamide, oral mizoribine was noninferior and well tolerated when used with glucocorticoid for induction therapy of active lupus nephritis. Mizoribine can be used as an alternative to intravenous cyclophosphamide as induction therapy for lupus nephritis. Trial Registration ClinicalTrials.gov Identifier: NCT02256150

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclophosphamideLupus NephritisRibonucleosidesImmunosuppressive AgentsHumansFemaleAdultMaleMiddle AgedAdministration, OralYoung AdultProspective StudiesTreatment OutcomeAdolescentAgedChina

Substanzen

mizoribineCyclophosphamideRibonucleosidesImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People's Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center fo…
  • Department of Nephrology, The Second Hospital of Jilin University, Changchun, Jilin, China.
  • Department of Nephrology, The First Affiliated Hospital of Air Force Medical University of PLA, Xi'an, Shaanxi, China.
  • Department of Nephrology, Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Department of Nephrology, Army Medical Center of PLA, Beijing, China.
  • Department of Nephrology, Liuzhou Worker's Hospital, Liuzhou, Guanxi, China.

Zitieren

APA

Dong, Z., Luo, P., Sun, S., Ni, Z., He, Y., Huang, X., Liu, Z., Wu, Z., Zhang, X., Liao, Y., Zhao, J., Lin, H., Zhang, X., Fu, R., Ding, G., Xu, Y., Wang, L., Xiao, Y., Shi, S., …, & Chen, X. (2025). Mizoribine or Cyclophosphamide for Lupus Nephritis. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2025.0648

Vancouver

Dong Z, Luo P, Sun S, Ni Z, He Y, Huang X, et al. Mizoribine or Cyclophosphamide for Lupus Nephritis. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2025.0648

BibTeX
@article{Dong2025,
  author = {Dong, Zheyi and Luo, Ping and Sun, Shiren and Ni, Zhaohui and He, Yani and Huang, Xiangyang and Liu, Zhangsuo and Wu, Zhenbiao and Zhang, Xinzhou and Liao, Yunhua and Zhao, Jianhong and Lin, Hongli and Zhang, Xiao and Fu, Rongguo and Ding, Guohua and Xu, Yan and Wang, Lihua and Xiao, Yuefei and Shi, Shumei and Zuo, Xiaoxia and Li, Zhanguo and Qiao, Li and Wang, Rong and Li, Wenge and Wan, Jianxin and Li, Ying and Guan, Tianjun and Deng, Xiaoli and Wu, Xiaoyan and Zheng, Hongguang and Chen, Jianghua and He, Lan and Yamaguchi, Seika and Wang, Hua and Cai, Guang-Yan and Zhang, Li and Chen, Xiangmei},
  title = {Mizoribine or Cyclophosphamide for Lupus Nephritis},
  journal = {JAMA Network Open},
  year = {2025},
  doi = {10.1001/jamanetworkopen.2025.0648}
}
Kostenlos starten →